Teva and OncoGenex Announce Initiation of Second Phase 3 Trial of Custirsen
Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced earlier today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen as first line therapy for the treatment of castrate-resistant prostate cancer.
The SYNERGY trial is the second of three Phase 3 trials to be initiated under a global collaboration and license agreement between Teva and OncoGenex to develop and commercialize custirsen.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.